Softgel Healthcare Private Limited — Phenylephrine Exporter Profile

Geopolitical & Trade Policy Impact on Softgel Healthcare Private Limited's Phenylephrine Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like SHPL. The Israel-Iran conflict has led to disruptions in Red Sea shipping routes, causing increased freight charges and extended transit times. These logistical challenges are particularly impactful for time-sensitive pharmaceutical shipments, potentially leading to supply chain disruptions and financial losses estimated between ₹2,500 crore and ₹5,000 crore in March 2026. (fortuneindia.com)

Conversely, trade tensions between the US and China have opened avenues for Indian pharmaceutical companies to expand their footprint in the US market. However, the imposition of tariffs on pharmaceutical imports by the US poses a significant risk. In August 2025, the US administration imposed broad tariffs on imports from over 60 countries, including India, with rates reaching as high as 39%. This move has raised concerns among Indian exporters about increased costs and potential loss of market share. (apnews.com)

In the European Union, compliance with the Falsified Medicines Directive (FMD) remains a critical requirement. Indian exporters must ensure adherence to these regulations to maintain access to the EU market. The India–EFTA Trade and Economic Partnership Agreement, signed in March 2024 and effective from October 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially benefiting exporters like SHPL. (en.wikipedia.org)